3rd Kinase Targeted Drug Discovery Summit

Memo

Propel Kinase Biology Understanding to Increase Selectivity, Overcome Resistance and Find the Optimal Combination Partner to Develop Best and First-in-Class Kinase Targeted Drugs The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly in targeted protein degradation. However, with ongoing challenges including selectivity and resistance in small molecule inhibitors, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs. Join us at the 3rd Kinase Targeted Drug Discovery Summit; the premier, target-specific conference designed to provide you with ground-breaking insights to revolutionize your kinase biology. Discover cutting-edge developments in small molecule therapeutics, including PROTACs, molecular glues, and allosteric inhibitors. Don't miss your opportunity to enhance drug selectivity, tackle resistance head-on, and identify optimal combination partners. Lead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes! URLs:Tickets: https://go.evvnt.com/2698121-2?pid=5569 Brochure: https://go.evvnt.com/2698121-3?pid=5569 Date and Time: On Tue, 11 Feb 2025 07:30 - Wed, 12 Feb 2025 14:45 Venue Details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:*Free* Drug Developer and Academic 2 Day Conference Pass: USD 0.50,Solution Provider Pricing - 2 Day Conference Pass: USD 3799.00 Speakers: Aleksey Gerasyuto, Vice President, Drug Discovery, Schrodinger, Bekim Bajrami, Associate Scientific Director, Biogen, Charbel Moussa, Scientific Director, KeifeRX, Douglas Thomson, Director and Head, Medicinal Chemistry, Proxygen, John Brognard, Senior Investigator, National Cancer Institute (NCI) in NIH, Kimberly Rizzolo, Principal Scientist, Novartis, Lars Van Der Veen, Chief Scientific Officer, iOnctura, Mark Fitzgerald, Director, Chemistry, Nested Therapeutics, Matthew L. Meyerso,n Director, Center for Cancer Genomics, Dana-Farber Cancer Institute, Randolph Lopez, Chief Technology Officer, A-Alpha Bio, Rayees Rahman, Chief Executive Officer, Harmonic Discovery, Susan Paprcka, Principal Investigator, Arcus Biosciences, Tim Owens, Senior Vice President and Head, Research, Alumnis